WO1999045021A1 - Genes regules par le cycle cellulaire - Google Patents
Genes regules par le cycle cellulaire Download PDFInfo
- Publication number
- WO1999045021A1 WO1999045021A1 PCT/US1999/004705 US9904705W WO9945021A1 WO 1999045021 A1 WO1999045021 A1 WO 1999045021A1 US 9904705 W US9904705 W US 9904705W WO 9945021 A1 WO9945021 A1 WO 9945021A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- probes
- cell cycle
- genes
- yeast
- regulated
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 125
- 230000022131 cell cycle Effects 0.000 title claims abstract description 98
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 51
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 40
- 230000014509 gene expression Effects 0.000 claims abstract description 15
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 12
- 239000002773 nucleotide Substances 0.000 claims abstract description 11
- 239000000523 sample Substances 0.000 claims description 81
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 33
- 210000005253 yeast cell Anatomy 0.000 claims description 21
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 230000001360 synchronised effect Effects 0.000 claims description 12
- 238000012360 testing method Methods 0.000 claims description 12
- 241000894007 species Species 0.000 claims description 8
- 108091033319 polynucleotide Proteins 0.000 claims description 7
- 102000040430 polynucleotide Human genes 0.000 claims description 7
- 239000002157 polynucleotide Substances 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 2
- 238000011144 upstream manufacturing Methods 0.000 abstract description 20
- 230000001419 dependent effect Effects 0.000 abstract description 19
- 238000013518 transcription Methods 0.000 abstract description 16
- 230000035897 transcription Effects 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 12
- 230000033228 biological regulation Effects 0.000 abstract description 11
- 230000000737 periodic effect Effects 0.000 abstract description 9
- 238000004458 analytical method Methods 0.000 abstract description 7
- 230000018486 cell cycle phase Effects 0.000 abstract description 4
- 230000002759 chromosomal effect Effects 0.000 abstract description 4
- 210000003527 eukaryotic cell Anatomy 0.000 abstract description 4
- 230000006698 induction Effects 0.000 abstract description 4
- 230000007246 mechanism Effects 0.000 abstract description 4
- 230000008520 organization Effects 0.000 abstract description 3
- 108700028146 Genetic Enhancer Elements Proteins 0.000 abstract description 2
- 238000012512 characterization method Methods 0.000 abstract description 2
- 241000235070 Saccharomyces Species 0.000 abstract 1
- 238000007619 statistical method Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 21
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 14
- 238000009396 hybridization Methods 0.000 description 13
- 239000012071 phase Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- 230000006870 function Effects 0.000 description 8
- 230000004543 DNA replication Effects 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000003491 array Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000000758 substrate Substances 0.000 description 5
- 108010031677 Anaphase-Promoting Complex-Cyclosome Proteins 0.000 description 4
- 102000005446 Anaphase-Promoting Complex-Cyclosome Human genes 0.000 description 4
- 108091035707 Consensus sequence Proteins 0.000 description 4
- 108091034057 RNA (poly(A)) Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000002966 oligonucleotide array Methods 0.000 description 4
- 230000002797 proteolythic effect Effects 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 3
- 101150033539 CLB2 gene Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 230000018199 S phase Effects 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000011278 mitosis Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108050006400 Cyclin Proteins 0.000 description 2
- 102000016736 Cyclin Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 101000824035 Homo sapiens Serum response factor Proteins 0.000 description 2
- 230000027311 M phase Effects 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108700005075 Regulator Genes Proteins 0.000 description 2
- 102100022056 Serum response factor Human genes 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- -1 diagnostics Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000022983 regulation of cell cycle Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 101150047137 ABF1 gene Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 101100086436 Caenorhabditis elegans rap-1 gene Proteins 0.000 description 1
- 108010031896 Cell Cycle Proteins Proteins 0.000 description 1
- 102000005483 Cell Cycle Proteins Human genes 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical group [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 229910021580 Cobalt(II) chloride Inorganic materials 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 102100024455 DNA repair protein SWI5 homolog Human genes 0.000 description 1
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 1
- 102100027479 DNA-directed RNA polymerase I subunit RPA34 Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000832371 Homo sapiens DNA repair protein SWI5 homolog Proteins 0.000 description 1
- 101100025200 Homo sapiens MSC gene Proteins 0.000 description 1
- 101001068636 Homo sapiens Protein regulator of cytokinesis 1 Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108700007119 Minichromosome Maintenance 1 Proteins 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 102100038169 Musculin Human genes 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101100420081 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) rps-0 gene Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 101100438011 Oryza sativa subsp. japonica BZIP12 gene Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 101150005828 SWI5 gene Proteins 0.000 description 1
- 101100127688 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) FAA1 gene Proteins 0.000 description 1
- 101100127691 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) FAA3 gene Proteins 0.000 description 1
- 101100033865 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RFA1 gene Proteins 0.000 description 1
- 101100524516 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RFA2 gene Proteins 0.000 description 1
- 101100524524 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RFA3 gene Proteins 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 108700021031 cdc Genes Proteins 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000024321 chromosome segregation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 229940094991 herring sperm dna Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000021121 meiosis Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- CJBPIZBHRWDBGQ-COSFPPCYSA-N rfa-1 Chemical compound C1([C@H]2N[C@H](CC3(N=C4C=5C6=C7O[C@](C6=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@@H](C)[C@@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC(=C4N3)C(=O)C=5C(O)=C7C)C)OC)C2)C=2C=CC=CC=2)=CC=CC=C1 CJBPIZBHRWDBGQ-COSFPPCYSA-N 0.000 description 1
- BINCGEGLXIMJFO-JQSLHUNDSA-N rfa-2 Chemical compound C1([C@H]2N[C@H](CC3(N=C4C=5C6=C7O[C@](C6=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@@H](C)[C@@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC(=C4N3)C(=O)C=5C(O)=C7C)C)OC)C2)C=2C=CC(F)=CC=2)=CC=C(F)C=C1 BINCGEGLXIMJFO-JQSLHUNDSA-N 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
- C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
- C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
Definitions
- the events of DNA replication, chromosome segregation, and mitosis define a fundamental periodicity in eukaryotic cell cycle. Precise coordination of the unidirectional transitions between these stages is critical to cell integrity and survival.
- Each of said probes comprises at least 12 nucleotides. Greater than 50 % of the probes in the set comprise portions of yeast genes which are cell cycle regulated. Cell cycle regulated yeast genes are defined as genes whose expression varies by more than 2-fold during the cell cycle of yeast.
- a method for identifying compounds which affect the cell cycle of yeast.
- Synchronized yeast cells are contacted with a test compound.
- RNA is isolated from the yeast cells.
- the amount of particular mRNA species in the RNA isolated from the yeast cells is determined using a set of polynucleotide probes. Each of said probes comprises at least 12 nucleotides. Greater than 50 % of the probes in the set comprise portions of yeast genes which are cell cycle regulated.
- Cell cycle regulated yeast genes are defined as genes whose expression varies by more than 2-fold during the cell cycle of yeast.
- a test compound is identified as a candidate drug if it is found to affect the amount of the particular mRNA species.
- RNA from synchronized yeast cells is isolated.
- the amount of particular mRNA species in the RNA isolated from the yeast cells is determined using probes.
- Each of said probes comprises at least 12 nucleotides.
- Greater than 50 % of the probes in the set comprise portions of yeast genes which are cell cycle regulated.
- Cell cycle regulated yeast genes are defined as genes whose expression varies by more than 2-fold during the cell cycle of yeast. The relative amounts of the particular mRNA species determined is characteristic of phase of cell cycle of the yeast.
- Fig. la Phase contrast photographs of yeast cells in various phases of the cell cycle as indicated.
- Fig. lb Graph of the percentage of cells that are unbudded (purple) small budded (yellow) , and large budded (green) versus time.
- Fig. lc Graph of the percentage of cells that are premitotic (red), mitotic (blue) and postmitotic (green) versus time. At 110 minutes, virtually all cells completed mitosis.
- Fig.2 Close-up views of high-density oligonucleotide arrays containing 25-mer probes for nearly every gene in the Saccharomyces cerevisiae genome, following hybridization with labeled cDNA from synchronized cells.
- the first column shows array features containing probes to the CJNl gene (highlighted in red) from different time points.
- the second column shows array features containing probes to the YML027w open reading frame. Transcript levels for both genes reached their maxima during late G, phase.
- transcripts which peaked in both late G ! and G 2 yellow
- transcripts which peaked in both S and M red
- Fig. 4 b transcripts which peaked singly in S
- transcripts which peaked singly in M green
- Fig.4c transcripts for the CLNl, CLN2, CLBl, and CLB2 cyclin genes Fig. Ad transcripts for MCM genes (mustard)
- transcripts for genes involved in DNA replication blue
- Figs. 5_ ⁇ -5o Phenotypic categorization of mRNAs which are regulated with the cell cycle.
- Fig. 6 Functional classifications of cell cycle-dependent transcripts which display cell cycle-specific periodicity. Biological functions of characterized genes were determined from the published literature and the MIPS database. Transcripts which peaked twice in one cell cycle are also listed.
- Fig. 7 Major functional groups of cell cycle-de pendent transcripts. ORF loci and names are listed for some genes detected as periodically transcribed by visual inspection of mRNA fluctuation patterns. Bioche mical functions were determined from the published literature and the MIPS database. Some of these transcriptional periodicities have been previously described.
- Fig. 8 Upstream regulatory elements in cell cycle-dependent transcription. Known and putative regulatory sequences and their frequency of occurrence in genes which display cell cycle-dependent mRNA Auction. Frequencey of occurrence is also shown for a random set of 300 genes from the yeast genome which do not show periodic mRNA Auction. Percent of genes in each category containing the regulatory sequence is listed in parentheses.
- the probes for each gene or mRNA may comprise at least 10, 12, 14, 16, 18, 20, 22, or 25 nucleotides, and are typically single stranded. Double stranded probes can also be used.
- the probes may comprise sense or antisense sequences, so long as they are derived from transcribed portions of the genome.
- the probes may be DNA or RNA and can also contain nucleotide analogues or non-nucleotide moieties, such as radiolabels, fluorescent labels, enzymes, etc.
- At least 50% of the probes in the sets comprise portions of genes whose expression varies by more than 2-fold during the cell cycle of yeast. Preferably at least 60, 75, 90, 95, 97, or 98 percent of the probes in the sets are from such cell cycle varying genes.
- the probes which are not such genes may be controls for hybridization, which are irrelevant or mismatched at one or more nucleotides.
- the sets may be of various sizes, depending on the purpose for which they are to be used. Typically the sets comprise at least 10, 20, 30, 40, 50, 100, 200, 300, 313, or 355 probes.
- the sets of probes can be used for any type of nucleic acid hybridization reactions known in the art. They may be used for solution hybridization or on a solid phase.
- RNA Ribonucleic acid
- cDNA Ribonucleic acid
- Solid phases which may be used include microtiter dishes, arrays, filter blots, etc.
- One particularly useful type of solid support is an array in which the probes are synthesized onto discrete locations on the solid support. See, e.g., Chee et al, Science 274, 610-614 (1996).
- Such arrays can contain many discrete probes in a very small area, for example greater than 1,000 or 10,000 in an area of 1.6 cm 2 .
- synchronized cells be used in the practice of the present invention. Cells can be synchronized using any techniques known in the art, including the use of conditional mutations and/or changes in the growth conditions of the cells.
- Test compounds which can be tested using the sets of probes of the present invention may be, for example, simple organic or inorganic compounds, natural or synthetic polymers, proteins, oligonucleotides, polypeptides, semisynthetic derivatives of natural products, natural product extracts. Mixtures of compounds or test substances may be tested, as can libraries of test compounds. Combinatorial libraries of compounds may be used, as can libraries of cloned nucleic acids or proteins they produce. Any substances which can be contacted with yeast cells can be tested. Similarly, forms of radiation can be tested for their effects using the sets of probes of the present invention.
- test compounds may be those which are being screened for toxic, mutagenic, carcinogenic, or therapeutic value.
- Compounds or treatments which cause a change in the pattern of expression of the monitored genes are potentially useful to alter cell cycle of eukaryotes. Such treatments may be useful as antifungal agents.
- Such assays may also be useful as prescreens for identifying anti-cancer or anti-viral therapies.
- the amount of hybridization of a test sample of RNA or DNA to a set of probes can be determined using any or the techniques or methods which are known in the art.
- the test sample can be labeled with a radiolabel or a fluorescent label.
- the amount of the label can be quantitated using appropriate instrumentation, such as a scintillation counter, an X-ray film, a fluorimeter.
- the amount of hybridization of the sets of probes to the samples collected from cells before and after treatment with a test compound, or treated and untreated can be readily compared.
- transcript levels could result from the shift between the restrictive and permissive temperatures and from the state of cell cycle arrest.
- analysis was focused on data from cdc28-13 time points taken more than forty minutes past the point of release from arrest.
- a database of potential gene promoter sequences was created by extracting the 500 bp upstream of the translational start site of every gene in the genome. This data set was then searched for hexanucleotide and hepanucleotide sequences that occurred with disproportionate frequency in the upstream regions of one set of cell cycle-regulated genes. The nucleotides surrounding these short sequences were visually inspected to determine a longer consensus sequence. For example, the sequence 5' GTAAACA 3' was found upstream of nearly 40% of the genes induced in G 2 and M, but upstream of less than 20% of genes induced at other times. After visual inspection of several G 2 and M gene promoter regions, this sequence was expanded to 5' AAAANGTAAACAA 3'. A search of non-coding sequence revealed that this sequence was found upstream of 14% of genes induced in G 2 , but upstream of less than 1% of other genes in the genome (Table 3). Another method of identifying candidate regulatory elements is examination of
- G 2 and M regulatory elements may be responsible for periodicity of mRNA abundance during these phases.
- G 2 and M regulatory elements maybe relatively rare, but highly specific in determining periodicity of transcript levels.
- regulatory sequences that affect transcription during these periods may be highly degenerate. Both methods described for identifying candidate regulatory elements
- telomeric or centromeric gene location was positioned directly adjacent to another gene induced in the same cell cycle phase (Fig. 3).
- the proportion of cell cycle regulated genes which would occupy adjacent positions by random chance is less than 3%. More than half of these gene pairs were transcribed divergently on opposite strands, many with fewer than 1500 bp bases separating their 5' ends.
- Periodic mRNA fluctuation was also observed in functional classifications of genes not previously associated with the cell cycle.
- transcripts for the FAA1, FAA3, and ELOl enzymes which participate in fatty acid biosynthesis, peaked during G,.
- Many of the nuclear-encoded mitochondrial enzymes required for glycolysis and oxidative phosphorylation were induced in early G, with very similar patterns of mRNA fluctuation. None of the transcripts for these mitochondrial genes peaked outside of G,.
- transcripts of both proteolytic effectors and substrates were examined for periodic changes in transcript levels. No periodic Auctuation was observed for any transcripts encoding constituents of the anaphase promoting complex (APC) or ubiquitin-dependent degradation pathway, which are involved in the proteolytic
- mRNA and protein expression patterns may provide clues to the function of previously uncharacterized genes.
- mRNA regulation is a strong indicator of biological function in the cell cycle, and it is likely that many of the uncharacterized genes in this screen have functions related to the cell cycle.
- periodicity of mRNA abundance was observed in fewer than 25% of all known CDC genes and genes known to be involved in mitosis, DNA replication, or other cell cycle-specific biological roles.
- poly(A)+RNA was purified from total RNA with an
- Oligotex dT-column selection step (Qiagen, Chatsworth, CA). Purified poly(A)+
- dT21 primer 10 mMDTT, 1st Strand Buffer (Gibco Life Technologies, Gaithersburg,
- RNA and primer were annealed for 10 min at 65°C, and the reaction was incubated at 42°C for 60 min.
- RNASE H RNASE H
- E. coli DNA polymerase I Gibco
- E. coli DNA ligase New England Biolabs, Beverly, MA
- the 600 :1 reaction volume was incubated at 16°C for 180 min.
- 30 units of T4 DNA polymerase (Gibco) were added to each reaction for 5 min at 16°C.
- Reactions were extracted with an equal volume of phenolxhloroform.
- Phase-Lock Gel (5 Prime-3 Prime, Inc., Boulder, CO) was used for all organic extractions to increase
- Double-stranded cDNA was ethanol precipitated and resuspended in 30 :1 of distilled water. cDNA was fragmented to an average length of 50 bp with addition of 3.5 :1 One-Phor-All buffer (Pharmacia Biotech, Piscataway, NJ), 2.2 :1 25 mM CoCl 2 (Boehringer Mannheim, Indianapolis, IN), and 0.15 units DNAse I (Gibco).
- 16 contains the cdcl5-2 allele (kindly provided by K. Nasmyth).
- Strain K3445 was grown overnight in YPAD (yeast extract/adenine/peptone/glucose, Difco Laboratories, Detroit, MI) at 25°C to a density of 8.0 10 6 cells/ml and divided into 50 ml aliquots. All samples were transferred to a 37°C shaking waterbath for 165 min. The cell cycle was reinitiated by moving the flasks to a 25°C shaking waterbath. Every 10 min, one 50 ml sample was
- Hybridizations were carried out at 42°C for 14 to 16 hr with
- biotinylated DNA was fiuorescently labeled by incubating with 2 :g/ml
- the arrays were read at a resolution of 7.5 :m using especially designed
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU28921/99A AU2892199A (en) | 1998-03-03 | 1999-03-03 | Cell cycle regulated genes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7665898P | 1998-03-03 | 1998-03-03 | |
US60/076,658 | 1998-03-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999045021A1 true WO1999045021A1 (fr) | 1999-09-10 |
Family
ID=22133420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/004705 WO1999045021A1 (fr) | 1998-03-03 | 1999-03-03 | Genes regules par le cycle cellulaire |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2892199A (fr) |
WO (1) | WO1999045021A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002022866A3 (fr) * | 2000-09-11 | 2003-06-05 | Pika Weihenstephan Gmbh | Procede et kit d'essai pour analyser une matiere contenant de l'acide nucleique |
US6846635B1 (en) | 1999-07-30 | 2005-01-25 | Large Scale Proteomics Corp. | Microarrays and their manufacture |
US7179638B2 (en) | 1999-07-30 | 2007-02-20 | Large Scale Biology Corporation | Microarrays and their manufacture by slicing |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5698686A (en) * | 1994-10-20 | 1997-12-16 | Arch Development Corporation | Yeast telomerase compositions |
US5801236A (en) * | 1994-03-18 | 1998-09-01 | Myriad Genetics, Inc. | Probes for MTS1 gene and polynucleotides encoding mutant MTS1 genes |
-
1999
- 1999-03-03 AU AU28921/99A patent/AU2892199A/en not_active Abandoned
- 1999-03-03 WO PCT/US1999/004705 patent/WO1999045021A1/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5801236A (en) * | 1994-03-18 | 1998-09-01 | Myriad Genetics, Inc. | Probes for MTS1 gene and polynucleotides encoding mutant MTS1 genes |
US5698686A (en) * | 1994-10-20 | 1997-12-16 | Arch Development Corporation | Yeast telomerase compositions |
Non-Patent Citations (2)
Title |
---|
O'CONNOR P. M., ET AL.: "CHARACTERIZATION OF THE P53 TUMOR SUPPRESSOR PATHWAY IN CELL LINES OF THE NATIONAL CANCER INSTITUTE ANTICANCER DRUG SCREEN AND CORRELATIONS WITH THE GROWTH-INHIBITORY POTENCY OF 123 ANTICANCER AGENTS.", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 57., no. 19., 1 October 1997 (1997-10-01), US, pages 4285 - 4300., XP002920858, ISSN: 0008-5472 * |
PLOCHOCKA-ZULINSKA D., RASMUSSEN G., RASMUSSEN C.: "REGULATION OF CALCINEURIN GENE EXPRESSION IN SCHIZOSACCHAROMYCES POMBE.", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 270., no. 42., 20 October 1999 (1999-10-20), US, pages 24794 - 24797., XP002920857, ISSN: 0021-9258 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6846635B1 (en) | 1999-07-30 | 2005-01-25 | Large Scale Proteomics Corp. | Microarrays and their manufacture |
US6887701B2 (en) | 1999-07-30 | 2005-05-03 | Large Scale Proteomics Corporation | Microarrays and their manufacture |
US7179638B2 (en) | 1999-07-30 | 2007-02-20 | Large Scale Biology Corporation | Microarrays and their manufacture by slicing |
WO2002022866A3 (fr) * | 2000-09-11 | 2003-06-05 | Pika Weihenstephan Gmbh | Procede et kit d'essai pour analyser une matiere contenant de l'acide nucleique |
Also Published As
Publication number | Publication date |
---|---|
AU2892199A (en) | 1999-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cohen et al. | Monitoring cellular responses to Listeria monocytogenes with oligonucleotide arrays | |
Duff et al. | Transgenic mouse models of Alzheimer's disease: how useful have they been for therapeutic development? | |
Cawley et al. | Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs | |
EP0743989B1 (fr) | Procédé d'identifcation des genes exprimés differentes | |
Cho et al. | A genome-wide transcriptional analysis of the mitotic cell cycle | |
Gilbert | Evaluating genome-scale approaches to eukaryotic DNA replication | |
EP3828285B1 (fr) | Transposition en une chromatine endogène permettant l'épigénomique personnelle | |
Kruse et al. | Tomo-seq: A method to obtain genome-wide expression data with spatial resolution | |
WO1998026098B1 (fr) | Procede de mesure de concentrations relatives en acides nucleique dans un melange complexe et extraction de sequences specifiques | |
Satterthwaite et al. | Differential gene expression in coronary arteries from patients presenting with ischemic heart disease: further evidence for the inflammatory basis of atherosclerosis | |
JP2004504059A (ja) | 転写された遺伝子を分析、及び同定するための方法、及びフインガープリント法 | |
Rafalski et al. | New experimental and computational approaches to the analysis of gene expression. | |
EP1255859A2 (fr) | Genes specifiques de tissu a signification diagnostique | |
Kapranov et al. | Beyond expression profiling: next generation uses of high density oligonucleotide arrays | |
Cox | Applications of nylon membrane arrays to gene expression analysis | |
JP2002335999A (ja) | ユニバーサルアレイを用いる遺伝子発現のモニター | |
WO1999045021A1 (fr) | Genes regules par le cycle cellulaire | |
US6509153B1 (en) | Genetic markers of toxicity preparation and uses | |
Gardiner et al. | Design, production, and utilization of long oligonucleotide microarrays for expression analysis in maize | |
JP2004524801A (ja) | Are含有遺伝子の発現を同定および分析するための方法 | |
JP2001509017A (ja) | イーストトランスクリプトームのキャラクタリゼーション | |
Scott et al. | P2P‐R expression is genetically coregulated with components of the translation machinery and with PUM2, a translational repressor that associates with the P2P‐R mRNA | |
Ando et al. | Efficient construction of cDNA microarrays utilizing normalized cDNA libraries of Arabidopsis thaliana | |
Nguyen et al. | DNA microarrays | |
US20040235008A1 (en) | Methods and compositions for profiling transcriptionally active sites of the genome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |